Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chongqing Genrix Biopharmaceutical Co Gross Margin %?
Chongqing Genrix Biopharmaceutical CoSHSE:688443 +0.81%43 Gross Margin % is 86.85% as of Mar. 2026, which is 123% above its 10-year median of 38.94. GuruFocus rates SHSE:688443 with a GF Score™ of 43/100. The stock has 4 warning signs investors should review. Among 733 Biotechnology companies, Chongqing Genrix Biopharmaceutical Co ranks better than 88.13% on this metric.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Chongqing Genrix Biopharmaceutical Co had a gross margin of 86.85% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Chongqing Genrix Biopharmaceutical Co Gross Margin % Related Terms
Chongqing Genrix Biopharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co Gross Margin % Chart
SHSE:688443 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Genrix Biopharmaceutical Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a Gross Margin % of 86.85% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. This is 123% above median its historical median of 38.94. According to the industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #87 out of 733 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Chongqing Genrix Biopharmaceutical Co's Gross Margin % too high?
Chongqing Genrix Biopharmaceutical Co's current Gross Margin % of 86.85% is 123% above median its 10-year median of 38.94. The Biotechnology industry median Gross Margin % is 60.91. Chongqing Genrix Biopharmaceutical Co's value of 86.85% is 42.6% above this industry median. Based on the distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #87 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #87 out of 733 companies for Gross Margin %. This places Chongqing Genrix Biopharmaceutical Co in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Chongqing Genrix Biopharmaceutical Co's value of 86.85% is 42.6% above this benchmark. While the company's 10-year median is 38.94 vs. the industry median of 60.91, Chongqing Genrix Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Genrix Biopharmaceutical Co's current Gross Margin % of 86.85% is 42.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Genrix Biopharmaceutical Co's current Gross Margin % is 86.85%, which is 123% above median its own 10-year median of 38.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a current Gross Margin % of 86.85%. The current Gross Margin % is 86.85%, which is 123% above median its 10-year median of 38.94 and 42.6% above the Biotechnology industry median of 60.91. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current Gross Margin % is 86.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chongqing Genrix Biopharmaceutical Co Business Description
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
43GF Score
Get the complete analysis for SHSE:688443
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688443 has been successfully added to your 
